{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:09:00Z","timestamp":1779170940868,"version":"3.51.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>It has been confirmed that cholesterol-lowering therapy, particularly the reduction of low-density lipoprotein cholesterol (LDL-C) levels, represents the most effective measure for decreasing the incidence of atherosclerotic cardiovascular disease and related cardiovascular events. Previous studies have shown that active reduction of cholesterol levels significantly increases the goal attainment rate of LDL-C and improves clinical outcomes. Although many cholesterol-lowering medications are currently available in clinical practice and the cholesterol lowering treatment status has improved, the real-world cholesterol management in China, especially the goal attainment rate of LDL-C, is not satisfactory. This issue is closely related to the selection of initial cholesterol-lowering treatment strategies. Furthermore, clinical research has demonstrated that the safety and adherence of cholesterol-lowering therapy are also critical factors influencing treatment effectiveness. In response, the National Cardiovascular Disease Expert Committee Cardiovascular Metabolic Medicine Professional Committee has organized domestic experts to systematically and comprehensively review methods and scientific choices for initiating cholesterol-lowering therapy in the Chinese population and developed a Chinese expert consensus on the selection of initial cholesterol-lowering strategies based on current evidence. It aims to propose optimized initial treatment regimens tailored to individual characteristics, thereby further improving the prevention and management of dyslipidemia in Chinese population.<\/jats:p>","DOI":"10.3389\/fphar.2026.1798787","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:43:32Z","timestamp":1779169412000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chinese expert consensus on the choice of initial cholesterol-lowering strategy"],"prefix":"10.3389","volume":"17","author":[{"given":"Na-Qiong","family":"Wu","sequence":"first","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Geriatric Cardiology, National Clinical Research Centre for Geriatric Disease, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Center for Cardiovascular Translational Research, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Quan","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Gang","family":"Yang","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Fei","family":"Dou","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Fei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Quan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na-Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Guang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1517\/14656560903376186","article-title":"Non-adherence to statin therapy: a major challenge for preventive cardiology","volume":"10","author":"Bates","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.123.320609","article-title":"Evinacumab and cardiovascular outcome in patients with homozygous familial hypercholesterolemia","volume":"44","author":"B\u00e9liard","year":"2024","journal-title":"Arteriosclerosis, Thrombosis, Vasc. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"118517","DOI":"10.1016\/j.atherosclerosis.2024.118517","article-title":"The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): nine-year data from the lomitapide observational worldwide evaluation registry (lower)","volume":"395","author":"Blom","year":"2024","journal-title":"Atherosclerosis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"","journal-title":"Eur. Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/joim.20029","article-title":"Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease","volume":"297","author":"Cha","year":"2025","journal-title":"J. Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12933-024-02498-3","article-title":"Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention","volume":"23","author":"Choo","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on european atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1346-8138.1996.tb02661.x","article-title":"A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma","volume":"23","author":"Fujita","year":"1996","journal-title":"J. Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jacc.2008.05.046","article-title":"Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22) analysis","volume":"52","author":"Giraldez","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023","volume":"86","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"Jama"},{"key":"B23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.5853\/jos.2022.02957","article-title":"Moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target low-density lipoprotein cholesterol goal achievement in patients with recent ischemic stroke: a randomized controlled trial","volume":"25","author":"Hong","year":"2023","journal-title":"J. Stroke"},{"key":"B25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41598-024-51310-5","article-title":"Comparative effectiveness of moderate-intensity Statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study","volume":"14","author":"Jang","year":"2024","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better--LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3969\/j.issn.1000-3614.2022.07.009","article-title":"Efficacy and safety of hybutimibe in the treatment of primary hypercholesterolemia: a multicenter, randomized, double-blind, placebo-controlled phase iii trial","volume":"37","author":"Jiyan","year":"2022","journal-title":"Chin. Circulation J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurjpc\/zwae081","article-title":"Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study","volume":"31","author":"Jun","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00392-020-01740-8","article-title":"Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-c","volume":"111","author":"Katzmann","year":"2022","journal-title":"Clin. Res. Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","article-title":"PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis","volume":"377","author":"Khan","year":"2022","journal-title":"Bmj"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e185554","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jacc.2023.05.042","article-title":"Combination lipid-lowering therapy in patients undergoing percutaneous coronary intervention","volume":"82","author":"Lee","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/ehjcvp\/pvad083","article-title":"Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability","volume":"10","author":"Lee","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e030414","DOI":"10.1161\/JAHA.123.030414","article-title":"Intensive statin therapy versus upfront combination therapy of statin and ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS data","volume":"12","author":"Lewek","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.3213","article-title":"Chinese expert consensus on the clinical diagnosis and management of statin intolerance","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40265-024-02113-5","article-title":"Moderate-intensity statin plus ezetimibe: time to rethink it as an optimal initial lipid-lowering strategy","volume":"85","author":"Li","year":"2025","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"101444","DOI":"10.1016\/j.trim.2021.101444","article-title":"Efficacy evaluation of PCSK9 monoclonal antibody (evolocumab) in combination with rosuvastatin and ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): a retrospective analysis from a single center in China","volume":"71","author":"Liu","year":"2022","journal-title":"Transpl. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1454918","DOI":"10.3389\/fcvm.2024.1454918","article-title":"The efficacy and safety of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis","volume":"11","author":"Liu","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e2127573","DOI":"10.1001\/jamanetworkopen.2021.27573","article-title":"Prevalence of dyslipidemia and availability of lipid-lowering medications among primary health care settings in China","volume":"4","author":"Lu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B47","doi-asserted-by":"publisher","first-page":"107647","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107647","article-title":"Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): a randomized clinical trial","volume":"33","author":"Lv","year":"2024","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejim.2024.02.004","article-title":"Impact of early initiation of ezetimibe in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"124","author":"Mahajan","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/08998280.2025.2487966","article-title":"Ezetimibe plus statin combination versus double-dose statin in patients with dyslipidemia and atherosclerotic cardiovascular disease risk: a comprehensive systematic review and meta-analysis of 47 randomized controlled trials","volume":"38","author":"Mahmoud","year":"2025","journal-title":"Proc. (Bayl Univ. Med. Cent.)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-020-01308-w","article-title":"Bempedoic acid: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","article-title":"Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy","volume":"22","author":"Masana","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10557-021-07310-y","article-title":"Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany","volume":"37","author":"Michaeli","year":"2023","journal-title":"Cardiovasc Drugs Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3969\/j.issn.1000-3614.2025.06.001","article-title":"Report on cardiovascular health and diseases in China 2024:an updated summary","volume":"40","year":"2025","journal-title":"Chin. Circulation J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/jca.21839","article-title":"Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: experience from Australia and New Zealand","volume":"36","author":"Page","year":"2021","journal-title":"J. Clin. Apher."},{"key":"B61","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J. Intern Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1210\/clinem\/dgad714","article-title":"Comparison of the efficacy of ezetimibe combination therapy and high-intensity statin monotherapy in type 2 diabetes","volume":"109","author":"Park","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ehjcvp\/pvaf004","article-title":"Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction","volume":"11","author":"Patti","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-c and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK lipoprotein apheresis registry, 1989\u20132017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"Raber","year":"2022","journal-title":"Jama"},{"key":"B68","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med. Care"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1007\/s12325-021-01892-7","article-title":"Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe","volume":"38","author":"Rea","year":"2021","journal-title":"Adv. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.amjmed.2005.09.014","article-title":"Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) trial","volume":"118","author":"Rouleau","year":"2005","journal-title":"Am. J. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial","volume":"15","author":"Rubino","year":"2021","journal-title":"J. Clin. Lipidol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"104653","DOI":"10.1016\/j.phrs.2020.104653","article-title":"Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: new therapeutic approaches for the treatment of atherogenic dyslipidemia","volume":"153","author":"Ruscica","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1461416","DOI":"10.3389\/fcvm.2025.1461416","article-title":"Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin-ezetimibe as a lipid-lowering therapy","volume":"12","author":"Samnaliev","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/s0735-1097(01)01783-1","article-title":"Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST)","volume":"39","author":"Sawayama","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur. Heart J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"Jama"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3760\/cma.j.cn112148-20230105-00009","article-title":"Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase iii clinical trial","volume":"51","author":"Siyu","year":"2023","journal-title":"Chin. J. Cardiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.4093\/dmj.2024.0482","article-title":"Comparative efficacy of initial statin and ezetimibe combination versus statin monotherapy on cardiovascular outcomes in diabetes mellitus: a nationwide cohort study","author":"Sohn","year":"2025","journal-title":"Diabetes Metab."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"Jama"},{"key":"B87","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12872-024-04144-y","article-title":"The clinical effectiveness and safety of low\/moderate-intensity statins and ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis","volume":"24","author":"Sydhom","year":"2024","journal-title":"BMC Cardiovasc. Disord."},{"key":"B88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-mono randomized clinical trial","volume":"86","author":"Taub","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5551\/jat.40204","article-title":"Statin responses in chinese patients","volume":"25","author":"Tomlinson","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"B91","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1253\/circj.CJ-17-0193","article-title":"Effect of ezetimibe on stabilization and regression of intracoronary plaque - the ZIPANGU study","volume":"81","author":"Ueda","year":"2017","journal-title":"Circ. J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e000134","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40258-025-00971-y","article-title":"Cost-effectiveness analysis of evolocumab or inclisiran in combination with statins versus statin monotherapy among patients with ASCVD in China","volume":"23","author":"Wang","year":"2025","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial","volume":"84","author":"Xu","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5551\/jat.e610","article-title":"Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan","volume":"15","author":"Yamashita","year":"2008","journal-title":"J. Atheroscler. Thromb."},{"key":"B99","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","article-title":"Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk","volume":"39","author":"Yang","year":"2017","journal-title":"Clin. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/CLEP.S507761","article-title":"Real-World assessment of the Association between PCSK9i adherence and LDL reduction and variability in a Chinese clinical practice","volume":"17","author":"Ye","year":"2025","journal-title":"Clin. Epidemiology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"oeae074","DOI":"10.1093\/ehjopen\/oeae074","article-title":"A real-world analysis of adherence, biochemical outcomes, and healthcare costs in patients treated with rosuvastatin\/ezetimibe as single-pill combination vs. free combination in Italy","volume":"4","author":"Zambon","year":"2024","journal-title":"Eur. Heart J. Open"},{"key":"B102","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","article-title":"Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia international study (DYSIS)","volume":"235","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","article-title":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial","volume":"233","author":"Zhao","year":"2014","journal-title":"Atherosclerosis"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1798787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:43:36Z","timestamp":1779169416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1798787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":103,"alternative-id":["10.3389\/fphar.2026.1798787"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1798787","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1798787"}}